What is Zacks Research's Forecast for Integer Q3 Earnings?

Integer Holdings Co. (NYSE:ITGR - Free Report) - Equities research analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Integer in a research report issued to clients and investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $1.67 for the quarter, down from their prior forecast of $1.69. The consensus estimate for Integer's current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer's FY2025 earnings at $6.33 EPS and Q1 2026 earnings at $1.60 EPS.

Other research analysts also recently issued reports about the company. Truist Financial set a $150.00 target price on Integer and gave the company a "buy" rating in a research report on Friday, April 25th. Oppenheimer downgraded Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. KeyCorp lowered their target price on Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and increased their target price for the company from $133.00 to $140.00 in a research report on Thursday, May 22nd. Finally, Benchmark lowered their price target on Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $145.00.

Integer Price Performance

ITGR traded down $1.07 during trading on Monday, reaching $117.69. 342,138 shares of the company traded hands, compared to its average volume of 374,305. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. Integer has a 12-month low of $104.93 and a 12-month high of $146.36. The firm has a fifty day simple moving average of $118.60 and a 200 day simple moving average of $128.52. The company has a market cap of $4.11 billion, a P/E ratio of 35.03, a PEG ratio of 1.72 and a beta of 1.03.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $437.39 million during the quarter, compared to analyst estimates of $428.51 million. During the same period last year, the firm posted $1.14 EPS. The company's revenue was up 7.3% on a year-over-year basis.

Insider Transactions at Integer

In other news, CEO Joseph W. Dziedzic sold 338,975 shares of Integer stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the sale, the chief executive officer now directly owns 47,000 shares in the company, valued at approximately $5,788,990. This trade represents a 87.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.16% of the company's stock.

Institutional Trading of Integer

Several institutional investors and hedge funds have recently made changes to their positions in ITGR. Raymond James Financial Inc. bought a new stake in shares of Integer in the fourth quarter valued at about $38,073,000. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Integer in the first quarter valued at about $33,337,000. Capital Research Global Investors raised its holdings in shares of Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock valued at $186,960,000 after acquiring an additional 194,895 shares in the last quarter. Artisan Partners Limited Partnership bought a new stake in shares of Integer in the fourth quarter valued at about $22,775,000. Finally, Nuveen LLC bought a new stake in shares of Integer in the first quarter valued at about $17,634,000. 99.29% of the stock is currently owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.